Comparison of the blood pressure-lowering effects and tolerability of losartan- and amlodipine-based regimens in patients with isolated systolic hypertension

Clinical Therapeutics

Volumn 25, Issue 5, 2003, Pages 1469-1489

  Volpe, Massimo ^a,b   Junren, Zhu ^c   Maxwell, Thomas ^o   Rodriguez, Aldo ^d   Gamboa, Raul ^e   Gomez Fernandez, Pablo ^f   Ortega Gonzalez, Ginés ^g   Matadamas, Norberta ^h   Rodriguez, Freddy ⁱ   Dass, Badal ^o   Kyle, Chris ^o   Clarysse, Laurent ^o   Bryce, Alfonso ^j   Moreno Heredia, Ernesto ^k   Germano, Giuseppe ^a   Gilles, Leen ^l   Smith, Ronald D ^m   Sanderson, John E ⁿ  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c FUDAN UNIVERSITY   (China)

^d HOSPITAL NACIONAL ALBERTO SABOGAL SOLOGUREN   (Peru)

^e Perú   (Peru)

^f HOSPITAL DE JEREZ   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^h Hospital General de Acapulco   (Mexico)

ⁱ Department of Internal Medicine   (Venezuela)

^j Cardiogolf Clinica El Golf   (Peru)

^k HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^l Merck Sharp and Dohme   (Belgium)

^m MERCK RESEARCH LABORATORIES   (United States)

ⁿ CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^o Univ Studi di Roma La Sapienza ^*

more..

Author keywords

Angiotensin II receptor antagonist; Isolated systolic hypertension; Losartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN II ANTAGONIST; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO;

ADULT; AGED; ARTICLE; ASTHENIA; BREATHING DISORDER; CLINICAL TRIAL; COLD; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIAGNOSTIC VALUE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SELECTIVITY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; FLUSHING; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MULTICENTER STUDY; PATIENT CARE; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REDUCTION; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; XEROSTOMIA;

EID: 0037945481     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80133-9     Document Type: Article

References (31)

1. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2000.
2. Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Arch Intern Med. 1992;152:56-64.
3. Kannel WB, Sorlie P, Gordon T. Labile hypertension: A faulty concept? The Framingham Study. Circulation. 1980;61:1183-1187.
4. Himmelmann A, Hedner T, Hansson L, et al. Isolated systolic hypertension: An important cardiovascular risk factor. Blood Press. 1998;7:197-207.
5. Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: Analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001;37:869-874.
6. Cushman WC, Crespo CJ, Roccella EJ. The prevalence of stage 1 and stage 2+ isolated systolic hypertension in the United States (1988-94). Circulation. 1998;97:825. Abstract.
7. Farsang C, Garcia-Puig J, Niegowska J, et al, for the Losartan ISH Investigators Group. The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. J Hypertens. 2000;18:795-801.
8. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
9. Staessen JA, Thijs L, Gasowski J, et al. Treatment of isolated systolic hypertension in the elderly: Further evidence from the Systolic Hypertension in Europe (Syst-Eur) trial. Am J Cardiol. 1998;82:20R-22R.
10. Goa KL, Wagstaff AJ. Losartan potassium: A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs. 1996;51:820-845.
11. McIntyre M, Caffe SE, Michalak RA, Reid JL. Losartan, an orally active angiotensin (AT1) receptor antagonist: A review of its efficacy and safety in essential hypertension. Pharmacol Ther. 1997;74:181-194.
12. Byyny RL. Losartan potassium lowers blood-pressure measured by ambulatory blood-pressure monitoring. J Hypertension. 1995;13(Suppl 1):S29-S33.
13. Wilson TW, Lacourciere Y, Barnes CC, for the Canadian Cozaar Hyzaar Amlodipine Trial Study Group. The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. CMAJ. 1998;159:469-476.
14. Monterroso VH, Rodriguez Chavez V, Carbajal ET, et al, for the Losartan Trial Investigators. Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Adv Ther. 2000;17:117-131.
15. Goldberg Al, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75:793-795.
16. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20:671-681.
17. Conlin PR, Gerth WC, Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther. 2001;23:1999-2010.
18. Cushman WC, Brady WE, Gazdick LP, Zeldin RK. The effect of a losartan-based treatment regimen on isolated systolic hypertension. J Clin Hypertens (Greenwich). 2002;4:101-107.
19. Cozaar [package insert]. West Point, Pa: Merck & Co, Inc; 1998.
20. Norvasc [package insert]. New York: Pfizer Inc; 1996.
21. Webster J, Fowler G, Jeffers TA, et al. A companson of amlodipine with enalapril in the treatment of isolated systolic hypertension. Br J Clin Pharmacol. 1993;35:499-505.
22. Calvo C, Gude F, Abellan J, et al. A comparative evaluation of amlodipine and hydrochlorothiazide as monotherapy in the treatment of isolated systolic hypertension in the elderly. Clin Drug Invest. 2000;19:317-326.
23. Dahlof B, Lindholm LH, Carney S, et al, for the LOA Study Group. Main results of the Losartan Versus Amlodipine (LOA) study on drug tolerability and psychological general well-being. J Hypertens. 1997;15:1327-1335.
24. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995-1003.
25. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention For Endpoint reduction (LIFE) substudy. JAMA. 2002;288:1491-1498.
26. Ruiz-Gayo M, Somoza B, Bravo R, et al. Chronic losartan treatment decreases angiotensin II-mediated facilitation of noradrenaline release in the caudal artery of spontaneously hypertensive rats. Life Sci. 2000;67:3153-3162.
27. d'Uscio LV, Shaw S, Barton M, Luscher TF. Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: Role of blood pressure and endothelial function. Hypertension. 1998;31:1305-1310.
28. Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension. 1995;25:913-917.
29. Kabour A, Henegar JR, Devineni VR, Janicki JS. Prevention of angiotensin II induced myocyte necrosis and coronary vascular damage by lisinopril and losartan in the rat. Cardiovasc Res. 1995;29:543-548.
30. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000;101:1653-1659.
31. Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: Role of superoxide dismutase. Circulation. 2001;103:799-805.